Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-09-04
2007-09-04
Bunner, Bridget (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388230, C530S389200, C530S391300, C530S391700, C530S412000
Reexamination Certificate
active
10395741
ABSTRACT:
The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
REFERENCES:
patent: 5488032 (1996-01-01), Dower et al.
patent: 5965704 (1999-10-01), Lok et al.
patent: 6274710 (2001-08-01), Dumoutier et al.
patent: 2003/0170823 (2003-09-01), Presnell et al.
patent: 2004/0152125 (2004-08-01), Presnell et al.
patent: WO98/02542 (1998-01-01), None
patent: WO98/37193 (1998-08-01), None
patent: WO99/07848 (1999-02-01), None
patent: WO00/24758 (2000-05-01), None
patent: WO00/39161 (2000-07-01), None
patent: WO00/65027 (2000-11-01), None
patent: WO00/70049 (2000-11-01), None
patent: WO00/73457 (2000-12-01), None
patent: WO00/77037 (2000-12-01), None
patent: WO01/16318 (2001-03-01), None
patent: WO01/36467 (2001-05-01), None
patent: WO01/40467 (2001-06-01), None
patent: WO01/46422 (2001-06-01), None
patent: WO01/98342 (2001-12-01), None
patent: WO02/20569 (2002-03-01), None
patent: WO02/024912 (2002-03-01), None
patent: WO02/066647 (2002-08-01), None
patent: WO02/072607 (2002-09-01), None
patent: WO03/035096 (2003-05-01), None
Moore, G. Genetically engineered antibodies. Clin Chem 35(9): 1849-1853, 1989.
Ballow et al. Immunopharmacology, immunomodulation and immunotherapy. J Am Med Assoc 278(22: 2008-2017, 1997.
Dillman et al. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 19(8): 833-841, 2001.
Dumoutier et al., “Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL-20 Receptor Complexes of Two Types,”J. Immunol. 167:3545-3549, 2001.
Dumoutier, L et al., “Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10-Related T Cell-Derived Inducible Factor/IL-22,”J. Immunol. 166:7090-7095, 2001.
Kotenko et al., “Identification, Cloning, and Characterization of a Novel Soluble Receptor That Binds IL-22 and Neutralizes Its Activity,”J. Immunol. 166:7096-7013, 2001.
Xu et al., “A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist,”Proc. Nat. Acad. Sci. 98:9511-9516, 2001.
Gruenberg et al., “A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta,”Genes and Immunity 2:329-334, 2001.
Xie et al., “Interleukin (IL)-22, a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2-4 and IL-22R,”J. Biol. Chem. 275(40):31335-31339, 2000.
Dumoutier et al., “Cloning and Characterization of IL-10-Related T Cell -Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9,”Journal of Immunology 164: 1814-1819, 2000.
Dumoutier et al. “Human interleukin-10-related T cell-derived inducible factor: Molecular cloning and functional characterization as an hepatocyte-stimulating factor,”Proc. Nat. Acad. Sci. 97(18):10144-10149, 2000.
Dumoutier et al., IL-TIF/IL-22: genomic organziation and mapping of the human and mouse genes,Genes and Immunity. 1:488-494, 2000.
Xu, X. et al., EMBL Database, Chinese National Human Genome Center at Shanghai, H Oct. 2000: AV714177.
Incyte Pharmaceuticals, Inc. clone, 1999: SHLW01158999.
Wells, “Additivity of Mutational Effects In Proteins,”Biochemistry 29(37):8509-8517, 1990.
Liu et al., “Expression Cloning and Characterization of a Human IL-10 Receptor,”J. Immunol. 152:1821-1829, 1994.
Blumberg et al., “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function,”Cell 104:9-19, 2001.
Zhang et al., “Identification, Purification, and Characterization of a Soluble Interleukin (IL)-13-binding Protein,”J. Biochem. 272:9474-9480, 1997.
Kotenko et al., “Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes,”Oncogene 19:2557-2565, 2000.
Kotenko et al., “Identification of the Functional Interleukin-22 (IL-22) Receptor Complex,”J. Biochem. 276(4):2725-2732, 2001.
Wei et al., “Cloning and characterization of mouse IL-22 binding protein,”Genes and Immunity 34:204-211, 2003.
Bork et al., “Go hunting in sequence databases but watch out for the traps,”TIG 12(10):425-0426, 1996.
Bork, “Powers and Pitfalls in Sequence Analysis: the 70% Hurdle,”Genome Research 10:398-400, 2000.
Sempowski et al., “Subsets of Murine Fibroblasts Express Membrane-Bound and Soluble IL-4 Receptors,”J. Immonol. 152: 3606-3614, 1994.
Bork et al., “Predicting functions from protein sequences—where are the bottlenecks,”Nature Genetics 18:313-318, 1998.
Parrish-Novak et al., “Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes,”J. Biochem 277(49):47517-47523, 2002.
Uhlar et al., “Serum amyloid A, the major vertebrate acute-phase reactant,”Eur. J. Biochem. 265:501-523, 1999.
Hillier et al., GenBank Accession No. AA132964, Nov. 27, 1996.
Hillier et al., GenBank Accession No. T70354, Mar. 7, 1995.
Hillier et al., GenBank Accession No. T70439, Mar. 7, 1995.
Muzny et al., EMBL Database, AC007458, Jan. 23, 2003.
Chandrasekher Yasmin A.
Hughes Steven D.
Kindsvogel Wayne
Xu Wen-feng
Bunner Bridget
Schutzer Aaron A.
ZymoGenetics Inc.
LandOfFree
Anti-IL-TIF antibodies and methods of making does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL-TIF antibodies and methods of making, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-TIF antibodies and methods of making will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3740886